Sort by
Refine Your Search
-
, as well as connections to Duke initiatives in AI and data science. This search is distinct from, but complementary to, the Duke University Discovery AI Initiative https://academicjobsonline.org/ajo
-
Sanford School's Master of National Security Policy (MNSP), a hybrid mid-career degree program, are particularly encouraged to apply. More information on the MNSP can be found at https
-
Position Description We are hiring a research coordinator to facilitate the activities of grant-funded research (see https://sites.duke.edu/bablab/ ) and the Duke Interdisciplinary Behavioral
-
assays; collect and analyze data related to funded programs; maintain research records; communicate research activities through reports, manuscripts, abstracts, and presentations; attend research group
-
Fellow for its 2026-2028 cohort. Context: Civic Science Fellows Program The national Civic Science Fellows program ( https://civicsciencefellows.org/ ) brings together an interdisciplinary network of
-
https://academicjobsonline.org/ajo/jobs/32228 Duke University is an Affirmative Action/Equal Opportunity Employer committed to providing employment opportunity without regard to an individual's age
-
pages) through Academic Jobs Online: https://academicjobsonline.org/ajo/jobs/32866 . Dossiers received by November 15, 2026, are guaranteed consideration. For questions about the position, please
-
Senior Policy Analyst, Duke Margolis Institute for Health Policy Hybrid (Washington DC or Durham NC)
variety of complex activities in research, writing, and analysis of quantitative and/or qualitative data within the scope of research and policy projects at Duke University. The anticipated hire will
-
Senior Policy Analyst, Duke Margolis Institute for Health Policy Hybrid (Washington DC or Durham NC)
scholarship at every level. Occupational Summary Duke-Margolis is hiring a Senior Policy Analyst to join the Institute’s Biomedical Innovation research team, with a primary focus on real-world data and
-
generation, innovative clinical trial design, drug development policy, real-world data and evidence, rare diseases, and/or the use and adoption of emerging technologies such as cell and gene therapies